Axonics Inc
NASDAQ:AXNX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
56.67
70.98
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Axonics Inc
Axonics Inc
Total Receivables
Axonics Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Axonics Inc
NASDAQ:AXNX
|
Total Receivables
$62.6m
|
CAGR 3-Years
33%
|
CAGR 5-Years
129%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Total Receivables
$3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Receivables
$2.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Receivables
$3.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Receivables
$7.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Receivables
$1.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
16%
|
|
Axonics Inc
Glance View
Axonics Inc., a prominent player in the medical technology landscape, has carved a niche for itself by focusing diligently on the development and commercialization of innovative solutions for bladder and bowel dysfunction. Founded in 2012, the company's primary product is its Sacral Neuromodulation (SNM) system, designed to treat urinary and fecal incontinence. What differentiates Axonics is its dedication to addressing a pervasive issue with an underpinning focus on patient-centric design and effective long-term treatment. Its SNM system offers users rechargeable batteries, providing a less invasive and more cost-effective solution compared to traditional systems. This technology not only addresses significant medical needs but also aligns well with a growing trend toward minimally invasive solutions in medtech. The operational model of Axonics is straightforward yet well-suited to drive profitability. Revenues primarily derive from the sales of its SNM system, which is marketed directly to healthcare providers and practitioners. This involves an intricate network of sales representatives and a hands-on approach to training medical professionals on the benefits and use of their systems, ensuring that the technology translates efficiently into patient treatment. By focusing extensively on a specific segment within the broader medical device industry, Axonics has positioned itself to capitalize on a substantial market opportunity, driven by an aging population and increasing rates of incontinence-related conditions. This strategic approach not only underscores its commitment to delivering effective healthcare solutions but also signifies its potential for sustained growth within a competitive landscape.
See Also
What is Axonics Inc's Total Receivables?
Total Receivables
62.6m
USD
Based on the financial report for Sep 30, 2024, Axonics Inc's Total Receivables amounts to 62.6m USD.
What is Axonics Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
129%
Over the last year, the Total Receivables growth was 28%. The average annual Total Receivables growth rates for Axonics Inc have been 33% over the past three years , 129% over the past five years .
You don't have any saved screeners yet